

Kyu-Sung Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7607989/publications.pdf>

Version: 2024-02-01

88
papers

2,193
citations

201674

27
h-index

243625

44
g-index

88
all docs

88
docs citations

88
times ranked

2259
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of a deep learning-based diagnostic platform to evaluate lower urinary tract disorders in men using simple uroflowmetry. <i>Investigative and Clinical Urology</i> , 2022, 63, 301.	2.0	5
2	Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study. <i>International Neurourology Journal</i> , 2022, 26, 119-128.	1.2	4
3	Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study. <i>Advances in Therapy</i> , 2021, 38, 739-757.	2.9	1
4	Mirabegron has longer treatment persistence than antimuscarinics: A real-world data from a Korean national cohort database. <i>Neurourology and Urodynamics</i> , 2021, 40, 1972-1980.	1.5	4
5	Comparison of Efficacy of Different Surgical Techniques for Benign Prostatic Obstruction. <i>International Neurourology Journal</i> , 2021, 25, 252-262.	1.2	9
6	Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021, 13, 98-107.	1.3	3
7	What Are the Success Factors for a Partnership with Global Medical Device Companies? Evidence from Korea. <i>Journal of Open Innovation: Technology, Market, and Complexity</i> , 2021, 7, 237.	5.2	4
8	Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH). <i>European Urology Focus</i> , 2020, 6, 729-737.	3.1	42
9	Expandable and implantable bioelectronic complex for analyzing and regulating real-time activity of the urinary bladder. <i>Science Advances</i> , 2020, 6, .	10.3	34
10	A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study). <i>Neurourology and Urodynamics</i> , 2020, 39, 2417-2424.	1.5	7
11	The long-lasting post-stimulation inhibitory effects of bladder activity induced by posterior tibial nerve stimulation in unanesthetized rats. <i>Scientific Reports</i> , 2020, 10, 19897.	3.3	6
12	The prevalence of urinary incontinence in men and women aged 40 years or over in China, Taiwan and South Korea: A cross-sectional, prevalence-based study. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 223-234.	1.3	10
13	Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial. <i>European Urology</i> , 2020, 77, 644-651.	1.9	40
14	Clinical guidelines for interstitial cystitis/bladder pain syndrome. <i>International Journal of Urology</i> , 2020, 27, 578-589.	1.0	122
15	Changes in uroplakin expression in the urothelium of patients with ulcerative interstitial cystitis/bladder pain syndrome. <i>Investigative and Clinical Urology</i> , 2020, 61, 304.	2.0	8
16	Efficacy and Safety of Naftopidil in Patients With Neurogenic Lower Urinary Tract Dysfunction: An 8-Week, Active-Controlled, Stratified-Randomized, Double-Blind, Double-Dummy, Parallel Group, Noninferiority, Multicenter Design. <i>International Neurourology Journal</i> , 2020, 24, 163-171.	1.2	1
17	Robotic Sacrocolpopexy for Treatment of Apical Compartment Prolapse. <i>International Neurourology Journal</i> , 2020, 24, 97-110.	1.2	8
18	Establishment and Validation of Extra-transitional Zone Prostate Specific Antigen Density (ETzD), a Novel Structure-based Parameter for Quantifying the Oncological Hazard of Prostates with Enlarged Stroma. <i>Scientific Reports</i> , 2019, 9, 770.	3.3	2

#	ARTICLE	IF	CITATIONS
19	What Are the Features of Successful Medical Device Start-Ups? Evidence from KOREA. Sustainability, 2019, 11, 1948.	3.2	16
20	A new approach to urinary bladder control with optogenetics. Investigative and Clinical Urology, 2019, 60, 61.	2.0	2
21	Can the Penile Cuff Test Predict the Outcome of Holmium Laser Enucleation of the Prostate for Benign Prostatic Obstruction?. Urology, 2019, 124, 207-212.	1.0	0
22	Prevalence of overactive bladder in <sc>C</sc>hina, <sc>T</sc>aiwan and <sc>S</sc>outh <sc>K</sc>orea: <sc>R</sc>esults from a cross-sectional, population-based study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 48-55.	1.3	74
23	Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan, and South Korea: Subgroup analysis of a cross-sectional, population-based study. LUTS: Lower Urinary Tract Symptoms, 2019, 11, O78-O84.	1.3	14
24	Current surgical management of pelvic organ prolapse: Strategies for the improvement of surgical outcomes. Investigative and Clinical Urology, 2019, 60, 413.	2.0	27
25	A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure. International Neurourology Journal, 2019, 23, 30-39.	1.2	1
26	A new approach to urinary bladder control with optogenetics. Investigative and Clinical Urology, 2019, 60, 61.	2.0	0
27	Efficacy of Holmium Laser Transurethral Incision of the Prostate in Symptomatic Mild-to-Moderate Benign Prostate Enlargement Based on Preoperative Characteristics. LUTS: Lower Urinary Tract Symptoms, 2018, 10, 231-236.	1.3	9
28	Predictive Factors of De Novo Overactive Bladder After Artificial Urinary Sphincter Implantation in Men With Postprostatectomy Incontinence. Urology, 2018, 113, 215-219.	1.0	10
29	Therapeutic effects of endoscopic ablation in patients with Hunner type interstitial cystitis. BJU International, 2018, 121, 659-666.	2.5	19
30	Innovative Distribution Priorities for the Medical Devices Industry in the Fourth Industrial Revolution. International Neurourology Journal, 2018, 22, S83-90.	1.2	12
31	Detecting Bladder Biomarkers for Closed-Loop Neuromodulation: A Technological Review. International Neurourology Journal, 2018, 22, 228-236.	1.2	11
32	Subjective health status of multimorbidity: verifying the mediating effects of medical and assistive devices. International Journal for Equity in Health, 2018, 17, 164.	3.5	7
33	Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. International Neurourology Journal, 2018, 22, 30-40.	1.2	12
34	Recent Patient Health Monitoring Platforms Incorporating Internet of Things-Enabled Smart Devices. International Neurourology Journal, 2018, 22, S76-82.	1.2	77
35	The prevalence and risk factors of nocturia in China, South Korea, and Taiwan: results from a cross-sectional, population-based study. World Journal of Urology, 2018, 36, 1853-1862.	2.2	22
36	The prevalence of lower urinary tract symptoms in population aged 40 years or over, in South Korea. Investigative and Clinical Urology, 2018, 59, 166.	2.0	31

#	ARTICLE	IF	CITATIONS
37	Change of Ultrasound Estimated Bladder Weight and Bladder Wall Thickness After Treatment of Bladder Outlet Obstruction With Dutasteride. LUTS: Lower Urinary Tract Symptoms, 2017, 9, 67-74.	1.3	3
38	Optogenetic Modulation of Urinary Bladder Contraction for Lower Urinary Tract Dysfunction. Scientific Reports, 2017, 7, 40872.	3.3	33
39	Diagnosing bladder outlet obstruction using the penile cuff test in men with lower urinary tract symptoms. Neurourology and Urodynamics, 2017, 36, 1884-1889.	1.5	10
40	Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (<sc>SYNERGY</sc> study). BJU International, 2017, 120, 562-575.	2.5	132
41	Tailoring pharmacotherapy for male lower urinary tract symptoms: A prospective, multicenter, observational trial. International Journal of Clinical Practice, 2017, 71, e12947.	1.7	2
42	Surgical Outcomes of Primary and Recurrent Female Urethral Diverticula. Urology, 2017, 105, 181-185.	1.0	9
43	Long-term outcomes of primary implantation and revisions of artificial urinary sphincter in men with stress urinary incontinence. Neurourology and Urodynamics, 2017, 36, 1930-1937.	1.5	19
44	Prevalence of Lower Urinary Tract Symptoms in China, Taiwan, and South Korea: Results from a Cross-Sectional, Population-Based Study. Advances in Therapy, 2017, 34, 1953-1965.	2.9	82
45	Biodegradation and Biocompatibility of Poly L-lactic Acid Implantable Mesh. International Neurourology Journal, 2017, 21, S48-54.	1.2	42
46	Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study. BMC Urology, 2017, 17, 108.	1.4	31
47	Clinical implications of underactive bladder. Investigative and Clinical Urology, 2017, 58, S75.	2.0	7
48	Surgical Outcomes and Safety of Robotic Sacrocolpopexy in Women With Apical Pelvic Organ Prolapse. International Neurourology Journal, 2017, 21, 68-74.	1.2	3
49	Assessing the Readjustable Sling Procedure (Remeex System) for Female Stress Urinary Incontinence With Detrusor Underactivity. International Neurourology Journal, 2017, 21, 116-120.	1.2	7
50	Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate. International Neurourology Journal, 2017, 21, 171-177.	1.2	12
51	Urinary Nerve Growth Factor as a Potential Biomarker of Treatment Outcomes in Overactive Bladder Patients. International Neurourology Journal, 2017, 21, 270-281.	1.2	10
52	New pharmacotherapy for treating overactive bladder: mirabegron and botulinum toxin. Journal of the Korean Medical Association, 2016, 59, 795.	0.3	0
53	Persistence and compliance with medication management in the treatment of overactive bladder. Investigative and Clinical Urology, 2016, 57, 84.	2.0	60
54	Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. International Journal of Urology, 2016, 23, 542-549.	1.0	100

#	ARTICLE	IF	CITATIONS
55	Drug persistence and compliance affect patient-reported outcomes in overactive bladder syndrome. Quality of Life Research, 2016, 25, 2021-2029.	3.1	13
56	Safety and efficacy of fesoterodine fumarate in patients with overactive bladder: results of a post-marketing surveillance study in Korea. Current Medical Research and Opinion, 2016, 32, 1361-1366.	1.9	2
57	Anatomical and Functional Outcomes of Prolift Transvaginal Mesh for Treatment of Pelvic Organ Prolapse. LUTS: Lower Urinary Tract Symptoms, 2016, 8, 159-164.	1.3	8
58	Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α -blocker in men with lower urinary tract symptoms (<scp>LUTS</scp>) and overactive bladder: a randomized controlled trial. BJU International, 2016, 117, 307-315.	2.5	11
59	Avoiding student infection during a Middle East respiratory syndrome (MERS) outbreak: a single medical school experience. Korean Journal of Medical Education, 2016, 28, 209-217.	1.3	50
60	Tension-Free Vaginal Tape (SECUR) Procedure for the Treatment of Female Stress Urinary Incontinence: 3-Year Follow-Up Results. LUTS: Lower Urinary Tract Symptoms, 2015, 7, 9-16.	1.3	4
61	The Impact of Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Depressive Symptoms, and Sexuality in Korean Men Aged 40 Years and Older: A Population-Based Survey. International Neurourology Journal, 2015, 19, 120-129.	1.2	34
62	Detrusor Overactivity with Impaired Contractility (DOIC) in the Elderly: Challenges in Management. Current Bladder Dysfunction Reports, 2015, 10, 278-287.	0.5	2
63	Surgical outcome of a repeat midurethral sling procedure after failure of a first procedure. International Urogynecology Journal, 2015, 26, 1759-1766.	1.4	6
64	Effect of Detrusor Overactivity on Functional Outcomes After Holmium Laser Enucleation of the Prostate in Patients With Benign Prostatic Obstruction. Urology, 2015, 86, 133-138.	1.0	13
65	Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β -adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourology and Urodynamics, 2015, 34, 685-692.	1.5	80
66	Efficacy of Holmium Laser Enucleation of the Prostate Based on Patient Preoperative Characteristics. International Neurourology Journal, 2015, 19, 278-285.	1.2	23
67	Nocturia. Journal of the Korean Medical Association, 2015, 58, 892.	0.3	1
68	Lower urinary tract dysfunction in the elderly. Journal of the Korean Medical Association, 2015, 58, 866.	0.3	0
69	The Prevalence of Lower Urinary Tract Symptoms in Korean Men Aged 40 Years or Older: A Population-Based Survey. International Neurourology Journal, 2014, 18, 126.	1.2	32
70	Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with <scp>H</scp>unner's lesion. International Journal of Urology, 2014, 21, 69-73.	1.0	35
71	Pelvic floor muscle training using an extracorporeal biofeedback device for female stress urinary incontinence. International Urogynecology Journal, 2013, 24, 831-838.	1.4	15
72	Effects of Doxazosin on Alpha 1 -Adrenergic Receptors in Prostates with Benign Prostatic Hyperplasia. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 82-89.	1.3	3

#	ARTICLE	IF	CITATIONS
73	Transurethral Procedures for Lower Urinary Tract Symptoms Resulting From Benign Prostatic Enlargement: A Quality and Meta-Analysis. <i>International Neurourology Journal</i> , 2013, 17, 59.	1.2	21
74	Patient-reported Goal and Goal Achievement: The Most Individualized Method of Outcome Assessment in Patients with Lower Urinary Tract Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2012, 4, 56-61.	1.3	1
75	Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population. <i>International Neurourology Journal</i> , 2012, 16, 77.	1.2	14
76	Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study. <i>World Journal of Urology</i> , 2011, 29, 185-190.	2.2	152
77	Prevalence of painful bladder syndrome/interstitial cystitis-like symptoms in women: a population-based study in Korea. <i>World Journal of Urology</i> , 2011, 29, 103-108.	2.2	27
78	Transobturator adjustable tape for severe stress urinary incontinence and stress urinary incontinence with voiding dysfunction. <i>International Urogynecology Journal</i> , 2011, 22, 341-346.	1.4	12
79	Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures. <i>International Urogynecology Journal</i> , 2010, 21, 1479-1483.	1.4	62
80	Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 117.	2.5	36
81	Comparison of Outcome Assessments in Patients with Overactive Bladder Receiving Anticholinergics. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, 40-44.	1.3	0
82	Prospective comparison of the "inside-out"™ and "outside-in"™ transobturator-tape procedures for the treatment of female stress urinary incontinence. <i>International Urogynecology Journal</i> , 2008, 19, 577-582.	1.4	64
83	Prevalence of nocturia in a Korean population aged 40 to 89 years. <i>Neurourology and Urodynamics</i> , 2008, 27, 60-64.	1.5	41
84	The Efficacy of Transurethral Resection of the Prostate in the Patients with Weak Bladder Contractility Index. <i>Urology</i> , 2008, 71, 657-661.	1.0	68
85	Pharmacological Therapy for Urinary Incontinence. <i>Journal of the Korean Medical Association</i> , 2007, 50, 1025.	0.3	4
86	Prevalence of urinary incontinence in Korean women:an epidemiologic survey. <i>International Urogynecology Journal</i> , 2007, 18, 1309-1315.	1.4	37
87	Depression and incontinence. <i>World Journal of Urology</i> , 2001, 19, 351-357.	2.2	106
88	Management of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients. , 0, , .		0